Research Overview
Peptides for Muscle Growth
A research overview of peptides studied for their effects on muscle protein synthesis, growth hormone secretion, and lean body mass.
Peptides investigated for muscle growth primarily work through the growth hormone axis, stimulating GH release or mimicking growth factors. These are distinct from anabolic steroids and operate through different biological pathways.
What This Page Covers
This page covers peptides studied for their potential to increase muscle mass, stimulate growth hormone release, or enhance anabolic signaling. The compounds listed range from MK-677, which has human clinical data for GH secretion and body composition, to growth hormone releasing peptides (GHRPs) with more limited clinical evidence. IGF-1 LR3 is a research-grade growth factor analog. None of these peptides are approved for muscle growth or athletic performance enhancement. Compounds on this page span a range of mechanisms, from anabolic signalling to tissue repair; the injury recovery condition overview provides physiological context for the repair-focused agents included here. Among the repair-focused compounds on this page, BPC-157 and TB-500 are the most frequently researched in musculoskeletal contexts, both carrying Animal Studies classifications.
How These Peptides May Influence Muscle Growth
Mechanism 01
Growth Hormone Secretagogue Activity
MK-677, GHRP-2, GHRP-6, and Hexarelin stimulate the pituitary gland to release growth hormone through ghrelin receptor or GHRP receptor activation. Elevated GH can increase IGF-1 levels, which promotes muscle protein synthesis.
Mechanism 02
Direct Growth Factor Signaling
IGF-1 LR3 is a modified insulin-like growth factor with extended half-life that directly activates muscle cell growth pathways. It bypasses the GH-pituitary axis entirely, acting at the tissue level.
Mechanism 03
Body Composition Modulation
GH-axis stimulation may shift body composition toward increased lean mass and reduced fat mass over time. However, the magnitude of muscle-specific effects varies and is often modest compared to direct anabolic interventions.
Peptides Commonly Discussed for Muscle Growth
Ordered by evidence level.
MK-677
Human TrialsGhrelin receptor agonism
Oral growth hormone secretagogue with human clinical data showing sustained GH and IGF-1 elevation. Studies demonstrate modest increases in lean body mass in specific populations.
IGF-1 LR3
Animal StudiesDirect IGF-1 receptor activation
Modified IGF-1 with extended half-life used as a research compound. Directly stimulates muscle cell proliferation and protein synthesis in preclinical models.
GHRP-2
Animal StudiesGHRP receptor agonism
Growth hormone releasing peptide that stimulates GH secretion via the ghrelin receptor. Human studies confirm GH elevation but muscle growth data is limited.
GHRP-6
Animal StudiesGHRP receptor agonism
Growth hormone releasing peptide with potent appetite-stimulating effects alongside GH secretion. Known for increasing hunger through ghrelin pathway activation.
Hexarelin
Animal StudiesGHRP receptor agonism
Synthetic hexapeptide GH secretagogue with documented GH-releasing activity in human studies. Subject to desensitization with repeated use.
BPC-157
Human TrialsTissue repair signaling
Pentadecapeptide studied extensively in animal models for tissue repair, with indirect relevance to muscle recovery through accelerated healing of damaged muscle tissue. Not studied for direct muscle hypertrophy. Mechanistic detail and evidence limitations for this compound are covered in the BPC-157 peptide profile.
TB-500
Animal StudiesActin regulation / anti-inflammatory
Synthetic fragment of thymosin beta-4 researched for systemic tissue repair and anti-inflammatory effects relevant to muscle recovery. Acts through actin regulation and cell migration rather than direct anabolic pathways. TB-500's mechanism, evidence classification, and distinction from thymosin beta-4 are documented in the TB-500 peptide profile.
Quick Comparison
| Peptide | Primary Mechanism | Evidence | Research Context |
|---|---|---|---|
| MK-677 | Ghrelin receptor agonism | Human Trials | Human clinical data; not FDA-approved |
| IGF-1 LR3 | Direct IGF-1 receptor activation | Animal Studies | Research compound; limited human data |
| GHRP-2 | GHRP receptor agonism | Animal Studies | Human GH elevation data; limited muscle outcomes |
| GHRP-6 | GHRP receptor agonism | Animal Studies | Human GH data; appetite stimulation documented |
| Hexarelin | GHRP receptor agonism | Animal Studies | Human GH data; desensitization observed |
| BPC-157 | Tissue repair signaling | Human Trials | Strong animal data; limited human evidence |
| TB-500 | Actin regulation / anti-inflammatory | Animal Studies | Primarily animal and in vitro data |
What the Research Suggests
Best Evidence for Muscle Growth
GH secretagogues reliably elevate growth hormone and IGF-1 levels in human studies. However, the translation from elevated GH levels to clinically significant muscle growth is modest and inconsistent. MK-677 has the most body composition data, showing small increases in lean mass. Neither BPC-157 nor TB-500 has sufficient human trial data to support clinical conclusions; both are Animal Studies-classified based primarily on animal and mechanistic research.
Strongest Individual Compound
MK-677 for sustained GH and IGF-1 elevation with modest lean body mass increases in elderly and GH-deficient populations. GHRPs for acute GH release, though long-term muscle growth data is sparse.
What This Category Cannot Do
Elevated growth hormone levels do not automatically produce significant muscle hypertrophy. The magnitude of lean mass changes in MK-677 studies is modest. IGF-1 LR3 lacks controlled human muscle growth trials. GHRPs show desensitization with chronic use (especially Hexarelin). None are approved for muscle growth or performance.
PSI Reading of the Evidence Gap
Muscle growth research through the GH axis covers compounds that reliably elevate GH and IGF-1 markers in human pharmacokinetic studies. MK-677 has the most human evidence in this category with documented improvements in muscle mass and bone density in older adult populations. The clinical significance of GH and IGF-1 elevation for muscle growth outcomes in healthy young adults is still developing. GH secretagogues and tissue repair peptides address different biological targets and should be evaluated separately for muscle-related applications.
How to Choose
Research-informed guidance for peptides studied in the context of muscle growth. Not a recommendation.
Regulatory Status
7 available through compounding.
Important Limitations
FDA-Approved
No peptides in this category are FDA-approved for muscle growth.
Research-Only
- MK-677: human clinical data, not approved
- IGF-1 LR3: research compound only
- GHRP-2, GHRP-6, Hexarelin: human GH data, not approved
Key Considerations
GH secretagogues may affect glucose metabolism and insulin sensitivity. IGF-1 LR3 carries theoretical proliferative risks. All compounds lack long-term safety data for muscle growth applications.
No peptide is FDA-approved for muscle growth, athletic performance, or bodybuilding.
Elevated growth hormone levels do not automatically produce significant muscle hypertrophy. The relationship is more complex than commonly assumed.
MK-677 lean mass increases in studies are modest (typically 1-2 kg) and may partly reflect water retention from GH effects.
IGF-1 LR3 is a research compound with safety concerns including potential for uncontrolled cell proliferation.
GH secretagogues can affect glucose metabolism, insulin sensitivity, and cortisol levels.
Explore More
Related Hubs
Who This May Apply To
Individuals interested in understanding the evidence base for growth hormone secretagogues and their actual effects on muscle mass.
Athletes or fitness-focused individuals evaluating peptide-based approaches to body composition and wanting factual evidence assessments.
Healthcare providers addressing patient questions about GH-related peptides for muscle and body composition goals.
Researchers studying the GH-IGF-1 axis and its relationship to skeletal muscle protein synthesis.
Related Conditions
This page is provided for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. The peptides discussed include both FDA-approved medications and research compounds that are not approved for clinical use. Always consult a qualified healthcare professional before making any decisions about medical treatments. The Peptide Science Institute is an independent research database and does not sell, prescribe, or recommend any compounds.